Patients with moderate-to-severe chronic kidney disease (CKD) are underrepresented in clinical trials of cardiac resynchronization therapy (CRT)-defibrillation (CRT-D) or CRT-pacing (CRT-P). We sought to determine whether outcomes after CRT-D are better than after CRT-P over a wide spectrum of CKD.
INTRODUCTION
Cardiac resynchronization therapy (CRT) is an established therapy for patients with heart failure (HF), impaired left ventricular (LV) function, and a wide QRS complex. 1 Some observational studies have suggested that CRT may be undermined by renal dysfunction. 2, 3 In the "real world," more than half of patients with HF have chronic kidney disease (CKD) stages 3-5. 4 This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The higher risk of sudden cardiac death (SCD) in CKD 5,6 enhances the "substrate" for defibrillation. In keeping with the hypothesis that the "sickest benefit the most," 7 the proportional benefit of CRT-defibrillation (CRT-D) should be greater in patients with CKD.
There is, however, uncertainty as to the benefit of implantablecardioverter defibrillators (ICDs) in patients with CKD. 8 In this respect, a meta-analysis of patient-level data from three randomized trials of primary prevention ICD found no benefit of ICD among 1,040 patients with estimated glomerular filtration rate (eGFR) < 60 mL/min. 9 Comparisons between CRT-D and CRT-pacing (CRT-P) in patients with CKD have not been undertaken.
In this observational study of real-world clinical practice, we have assessed the long-term outcomes of CRT according to preimplant renal function. Because of the restrictions on CRT-D placed by national guidelines, 10 our study population comprises a substantial proportion of CRT-P recipients. This provides a unique opportunity for a comparison of long-term outcomes of CRT-D and CRT-P.
METHODS
The study population consisted of patients undergoing a successful CRT device implantation for primary prevention in the period from 
Device therapy
Standard transvenous techniques under local anesthesia and intravenous sedation were used for device implantation. Thereafter, patients were followed-up in dedicated device therapy clinics on a 6-monthly basis; patients with events were assessed opportunistically according to clinical need. Device optimization using transmitral Doppler-directed optimization of atrioventricular delay using an iterative technique was undertaken up to 2013. In light of emerging evidence, routine echocardiographic optimization was abandoned.
Thereafter, optimization was only undertaken in symptomatic nonresponders. In patients in sinus rhythm, backup atrial pacing was set at 60 beats/min, and the pacing mode was set to DDDR with an interventricular delay of 0-4 ms. In patients with permanent atrial fibrillation, right ventricular and LV leads were implanted and a CRT generator was used, plugging the atrial port and programming to a ventricular triggered mode. Atrioventricular junction ablation was undertaken according to the physicians' discretion.
Endpoints
The primary endpoint was total mortality. Secondary endpoints included: cardiac mortality, which included cardiac transplantation or implantation of a LV assist device; the composite endpoint of total mortality or HF hospitalization; and the composite endpoint of total mortality or unplanned hospitalization for major adverse cardiac events (MACEs), which included hospitalization for HF, myocardial infarction, acute coronary syndrome, and arrhythmia (ventricular tachycardia, ventricular fibrillation, and atrial fibrillation). Stroke and pulmonary embolism were not considered as MACEs. Therapies delivered by CRT-D devices (antitachycardia pacing and shocks) were evaluated for appropriateness using electrograms. Only appropriate therapies were considered. In composite endpoints, the first event was used for censoring. Mortality data were collected through medical records and from interviews with patients' caregivers. Clinical events were collected every 6 months by investigators who were blinded to all other patient data, apart from demographics. These were adjudicated by blinded investigators on a 6-monthly basis.
Renal function
The GFR was estimated (eGFR) using the simplified formula derived from the Modification of Diet in Renal Disease (MDRD) study, which has been validated in patients with HF. 11 In data analysis, we have used the eGFR threshold of <60 mL/min per 1.73 m 2 in the definition of renal dysfunction. This cut-off has been used extensively in CRT studies. [12] [13] [14] 
Statistical analysis
Baseline characteristics were compared between patients with eGFR < 60 and ≥ 60 mL/min per 1.73 m 2 as well as across device types.
Continuous variables were expressed as mean ± standard deviation.
Normality was tested using the Shapiro-Wilk test. Comparisons between normally distributed continuous variables were analyzed using analysis of variance and categorical variables were analyzed using 2 tests. Kaplan-Meier curves and the log-rank test were used to assess cumulative survival. Multivariate Cox proportional hazard models were used to assess relative hazard rates comparing eGFR <60 and ≥60 mL/min per 1.73 m 2 as well as the impact of eGFR as a continuous measurement. Variables with a P < 0.10 on univariable analyses were entered in multivariate models, and further backward elimination was applied for the final multivariate models. Interactions between eGFR and device type was tested and interaction P-values for CRT-D versus CRT-P were reported for the two eGFR groups.
Proportionality hypotheses were verified by visual examination of log (survival) graphs to ensure parallel slopes and by examining Schoenfeld residuals. In P-spline analyses, predicted risks of total mortality were calculated considering eGFR as a continuous variable and an eGFR of 60 mL/min per 1.73 m 2 was used as reference. Separate analyses were undertaken for the interaction between CRT-D and CRT-P. Statistical analyses were undertaken using Stata 14 (StataCorp, College Station, TX, USA). A two-sided P ≤ 0.05 was considered statistically significant. 
TA B L E 1 Baseline characteristics

RESULTS
Baseline characteristics according to renal function
Of a total of 1,046 patients, 488 (42.8%) had a preimplant eGFR ≥ 60 and 598 (57.2%) an eGFR < 60. As shown in Table 1 , patients in eGFR < 60 were 6.8 years older (P < 0.001); were less likely to receive a CRT-D (P = 0.026); and were more likely to have ischemic cardiomyopathy (P = 0.001), diabetes (P = 0.030), hypertension (P = 0.009), a previous coronary artery bypass grafting (P = 0.004), and atrial fibrillation (P = 0.009). In addition, the eGFR < 60 group had a higher uptake of loop diuretics (P = 0.018) and a lower uptake of 
Outcomes according to renal function
As shown in Figure 1 Supplementary Figure S1 , Online Appendix.
The survival benefit of eGFR ≥ 60 was seen in most subgroups except for age < 59 or ≥ 80 years, female sex, NYHA class IV, with diabetes, and LVEF ≤ 0.25. In multivariate analyses ( 
Baseline characteristics according to device type
Over the study period, 1,046 patients underwent primary prevention CRT-D (n = 410 [39.2%]) or CRT-P (n = 636 [60.8%]). As shown in 1, significant differences emerged between CRT-D and CRT-P patients with respect to most baseline characteristics. Notably, CRT-D patients were 4.6 years younger (P < 0.001) and a greater proportion were men (P < 0.001). In addition, CRT-D patients had a lower NYHA class (76.4% in class III or IV, compared with 86.2% in CRT-P patients, P < 0.001) and a higher eGFR (by 2.6 mL/min per 1.73 m 2 , P = 0.042).
Outcomes according to device type
In univariate analyses, CRT-D patients had a lower crude total mortality (HR: 0.68; 95% CI: 0.55-0.84), total mortality or HF hospitalization (HR: 0.73; 95% CI: 0.60-0.88), total mortality or hospitalization for MACEs (HR: 0.74; 95% CI: 0.62-0.90), and cardiac mortality (HR: 0.67; 95% CI: 0.52-0.86). Figure 2 shows that the benefit of CRT-D over CRT-P was evident for both the eGFR < 60 and ≥ 60 groups.
In multivariate analyses (Table 2) , CRT-D was associated with a lower total mortality in both the eGFR groups (eGFR ≥ 60 aHR: 0.65; 95% CI: 0.45-0.95; eGFR < 60 aHR: 0.64; 95% CI: 0.48-0.85). A similar trend was observed for total mortality or HF hospitalization, total mortality or hospitalization for MACEs, and cardiac mortality. We did not find any device type/eGFR interaction when comparing CRT-D with CRT-P (all P > 0.5) ( Supplementary Table S2 , Online Appendix). The relative risks of total mortality increased and difference between CRT-D and CRT-P narrowed as the eGFR decreased below 60 (Supplementary Figure S2 , Online Appendix).
To explore possible effects of date of implantation on outcomes, we used different year dummies on survival analyses and found that date of implantation did not predict any of the endpoints (data not shown).
DISCUSSION
This is the largest study comparing mortality and morbidity after CRT-D and CRT-P in relation to preimplant renal function. We found that an eGFR < 60 was associated with a higher risk of total mortality, total mortality or HF hospitalization, total mortality or hospitalization for MACE, and cardiac mortality, compared to eGFR ≥ 60. Moreover, despite less favorable outcomes compared to the eGFR ≥ 60 group, CRT-D was associated with a lower total mortality and composite endpoints in the eGFR < 60 group.
Renal function and outcomes
We have observed that CKD was associated with a higher total mortality. Every 10 mL/min per 1.73 m 2 decrement in eGFR was associated with a 15% higher crude total mortality (9% after covariate adjustment). This is broadly consistent with several observational studies.
In a registry of 716 consecutive CRT recipients, a 10 mL/min per 1.73 m 2 decrement in eGFR was associated with an 18% higher total mortality. 15 In a study of 432 CRT-D recipients, the estimated 5-year mortality rose from 36.3% for CKD stage 1 to 62.1% for CKD stages 4 and 5. 16 In the National Cardiovascular Data Registry (ICD Registry), the 3-year mortality for CRT-D patients with end-stage renal failure was 54%. 2 In subgroup analyses (Figure 2) , the survival benefit of eGFR ≥ 60 was seen in most subgroups on total mortality, except for age (<59 years or ≥80 years), female sex, NYHA class IV, diabetes, or LVEF < 25%. With respect to female sex, several studies have shown a more favorable outcome from device therapy in women, [17] [18] [19] and it appears that the protective effect of female sex somehow overrides the effects of renal dysfunction. With respect to age, it is conceivable that the natural mortality expected at the age of ≥80 years overrides the effects of renal dysfunction. Arguably, severe pump failure, in the context of NYHA class IV or a LVEF < 25%, may also be expected to override renal dysfunction.
CRT-D versus CRT-P
We found that CRT-D was superior to CRT-P with respect total mortality, total mortality or HF hospitalization, total mortality or hospitalization for MACEs, and cardiac mortality. Importantly, the lower risk of these endpoints with CRT-D over CRT-P was evident in patients with an eGFR < 60, despite that these outcomes were worse than in the eGFR ≥ 60 group. This suggests that in CRT recipients, CRT-D is superior to CRT-P, regardless of renal function.
A subanalysis of MADIT-CRT (Multicenter Automatic Defibrillator
Implantation Trial-Cardiac Resynchronization Therapy) showed that although total mortality was higher in patients with an GFR < 60, compared to patients with an eGFR ≥ 60, the reduction in total mortality and total mortality or HF hospitalization was actually greater in the GFR < 60 group. 12 Importantly, MADIT-CRT compared CRT-D with ICD and, therefore, the reported findings relate to the effects resynchronization rather than defibrillation. In this study, which compares CRT-D versus CRT-P rather than CRT-D with ICD, the superior outcomes of CRT-D must, intuitively, be due to delivered antitachycardia pacing and shocks. However, the rate of delivered therapies was similar in both the eGFR groups. Why the same rate of such therapies should translate to better outcomes, in terms of total and cardiac mortality, even in patients with an eGFR < 60, is not immediately apparent. The possibility arises that, over and above the benefits of CRT, antitachycardia pacing or shocks carry a greater proportional survival advantage in advanced CKD (eGFR < 60).
Clinical application
Physicians may be tempted to avoid device therapy in patients with renal dysfunction, 20 given reports of poor outcomes and an increased risk of complications. 2 This study shows that after CRT, patients with CKD had a worse prognosis than patients with normal or mildly impaired renal function. Nevertheless, patients lived longer and were less likely to be hospitalized for HF or MACE after CRT-D than after CRT-P. These findings support the preferential use of CRT-D over CRT-P in patients with moderate CKD.
Limitations
This study has the limitations of an observational study. We did not include patients without CRT-D or CRT-P therapy as a control group and we cannot therefore comment on the relative benefit of device therapy over optimal medical therapy. Although we have included more patients with severe renal dysfunction than any other study (n = 84 with eGFR < 30 or end-stage renal failure), we lack statistical power to adequately compare CRT-D versus CRT-P in patients at these extremes of renal dysfunction. In addition, it is possible that renal dysfunction influenced the prescription and choice of device therapy, which was based on physician's decisions rather than by study design.
The national guidelines on CRT represent an a priori selection bias on device type selection which may have influenced outcomes. Notwithstanding, the group difference in eGFR was only marginal (2.6 mL/min per 1.73 m 2 ). We have no data as to the number of patients who were excluded from device therapy on the basis of renal dysfunction. A further limitation is the lack of data with regard to optimization of medical therapy following device implantation. Unfortunately, we lack data on the exact number of clinic visits per patient, or the reasons behind them. It is possible that differences in clinical follow-up could have influenced our results. Differences in the biventricular pacing uptake between the CRT-D and CRT-P groups, which were not addressed, could also account for differences in outcomes.
CONCLUSIONS
In CRT recipients, moderate CKD was associated with a higher total mortality and morbidity compared to normal renal function or mild CKD. Despite less favorable absolute outcomes, patients with moderate CKD had better outcomes from CRT-D than after CRT-P. These findings support the preferential use of CRT-D over CRT-P in patients with moderate CKD who are considered candidates for CRT.
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